Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review.

IF 6.3 2区医学 Q1 ALLERGY Clinical and Experimental Allergy Pub Date : 2024-11-07 DOI:10.1111/cea.14592

Hye Kyu Min, Sooji Lee, Soeun Kim, Yejun Son, Jaeyu Park, Hyeon Jin Kim, Jinseok Lee, Hayeon Lee, Lee Smith, Masoud Rahmati, Jiseung Kang, Nikolaos G Papadopoulos, Seong H Cho, Jong Woo Hahn, Dong Keon Yon

{"title":"Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review.","authors":"Hye Kyu Min, Sooji Lee, Soeun Kim, Yejun Son, Jaeyu Park, Hyeon Jin Kim, Jinseok Lee, Hayeon Lee, Lee Smith, Masoud Rahmati, Jiseung Kang, Nikolaos G Papadopoulos, Seong H Cho, Jong Woo Hahn, Dong Keon Yon","doi":"10.1111/cea.14592","DOIUrl":null,"url":null,"abstract":"Objective: Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden.Design: We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions.Data sources: PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases.Eligibility criteria for selection: We included general population-based observational studies on CRS published from database inception through October 20, 2023.Results: A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69-11.33; number of studies, 20) and 0.65% (95% CI, 0.56-0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980-2000: 4.72%; 95% CI, 2.12-10.49; 2014-2020: 19.40%; 95% CI, 12.12-31.07). Similar patterns were observed in CRS incidence.Conclusions: Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative.Systematic review registration: PROSPERO (registration no. CRD42024527805).","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":null,"pages":null},"PeriodicalIF":6.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cea.14592","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden.

Design: We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions.

Data sources: PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases.

Eligibility criteria for selection: We included general population-based observational studies on CRS published from database inception through October 20, 2023.

Results: A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69-11.33; number of studies, 20) and 0.65% (95% CI, 0.56-0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980-2000: 4.72%; 95% CI, 2.12-10.49; 2014-2020: 19.40%; 95% CI, 12.12-31.07). Similar patterns were observed in CRS incidence.

Conclusions: Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative.

Systematic review registration: PROSPERO (registration no. CRD42024527805).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

慢性鼻炎的全球发病率和流行率：系统回顾。

目的：有关全球慢性鼻炎（CRS）发病率的数据在不同国家和不同时期存在很大差异，而且数量有限。因此，我们旨在对 1980 年至 2021 年全球、地区和国家的 CRS 负担进行全面调查，并确定影响此类负担水平的因素：设计：我们对以普通人群为基础、关注 CRS 的观察性研究进行了系统回顾和荟萃分析。我们计算了 CRS 流行率和发病率的汇总估计值及 95% 的置信区间 (CI)。根据性别、年龄组、地理区域、吸烟状况、肥胖程度和合并症等因素进行了分组分析：数据来源：PubMed/MEDLINE、EMBASE、CINAHL、Google Scholar 和 Cochrane 数据库：我们纳入了从数据库建立之初到 2023 年 10 月 20 日发表的基于普通人群的 CRS 观察性研究：共有 28 项符合条件的研究被纳入分析，涵盖四大洲 20 个国家超过 2.37 亿名参与者和 11342923 名 CRS 患者。研究发现，CRS和CRS伴鼻息肉（CRSwNP）的全球汇总患病率分别为8.71%（95% CI，6.69-11.33；研究数量，20）和0.65%（95% CI，0.56-0.75；研究数量，4）。欧洲的 CRS 患病率高于北美、南美和亚洲；成人高于儿童；吸烟者高于从不吸烟者；肥胖者高于正常体重者；合并有哮喘、糖尿病、湿疹和鼻中隔偏曲等疾病者。从 1980 年到 2020 年，CRS 的汇总患病率有所上升（1980-2000 年：4.72%；95% CI，2.12-10.49；2014-2020 年：19.40%；95% CI，12.12-31.07）。在CRS发病率方面也观察到了类似的模式：我们的研究就不同人口和临床因素下的 CRS 流行率和发病率提供了有价值的见解，凸显了 CRS 日益加重的全球负担。国际上报告的 CRS 患病率不尽相同，而且可能会随着时间的推移而增加。为了提高数据质量和可比性，报告方法的标准化势在必行：系统综述注册：PROSPERO（注册号：CRD42024527805）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Allergy 医学-过敏

CiteScore

10.40

自引率

9.80%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field. In response to the increasing number of quality submissions, since 1996 the journals size has increased by over 30%. Clinical & Experimental Allergy is essential reading for allergy practitioners and research scientists with an interest in allergic diseases and mechanisms. Truly international in appeal, Clinical & Experimental Allergy publishes clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.